Levels of estrogen and progesterone receptors in the myometrium and leiomyoma tissue after suppression of estrogens with gonadotropin releasing hormone analogs

Gynecological Endocrinology

Volumn 15, Issue SUPPL. 6, 2001, Pages 61-68

  Van De Ven, J ^a,b   Sprong, M ^a   Donker, G H ^a   Thijssen, J H H ^a,b   Mak Kregar, S ^c   Blankenstein, M A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Ferring BV   (Netherlands)

Author keywords

Agonists; Estrogen receptors; Fibroids; GNRH; Goserelin; Leiomyoma; Myometrium; Progesterone receptors; Triptorelin; Uterus

Indexed keywords

DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; GONADORELIN; GOSERELIN; PROGESTERONE RECEPTOR; TRIPTORELIN;

ARTICLE; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEIOMYOMA; LUTEAL PHASE; MULTICENTER STUDY; MYOMETRIUM; RANDOMIZED CONTROLLED TRIAL; UTERUS CANCER;

ESTRADIOL; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEIOMYOMA; LUTEAL PHASE; MYOMETRIUM; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPTORELIN; UTERINE NEOPLASMS;

EID: 0009549072     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.15.s6.61.68     Document Type: Article

References (25)

1. Haney AF. Clinical decision making regarding leiomyomata: what we need in the next millennium. Environ Health Perspect 2000;108(Suppl 5): 835-9
2. Stewart EA. Uterine fibroids. Lancet 2001;357: 293-9
3. Robboy SJ, Bentley RC, Butnor K, et al. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 2000;108 (Suppl 5):779-84
4. Filicori M, Hall DA, Loughlin JS, et al. A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Fertil Steril 1983;147:726-7
5. Maheux R, Guilloteau CH, Lemay A, et al. Luteinizing hormone-releasing hormone agonist and uterine leiyomyoma: a pilot study. Am J Obstet Gynecol 1985;152:1034-7
6. Shaw RW. New approaches to the management of fibroids. Curr Opin Obstet Gynaecol 1991;3:859-64
7. Scialli AR, Levi AJ. Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri. Fertil Steril 2000;74:540-6
8. Crosignani PG, Vercellini P, Meschia M, et al. GnRH agonists before surgery for uterine leiomyomas. A review. J Reprod Med 1996;41:415-21
9. Kuhlmann M, Gartner A, Schindler EM, et al. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy. Gynecol Endocrinol 1997;11: 169-74
10. Friedman AJ, Daly M, Juneau-Norcross M, et al. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod 1994; 9:1618-25
11. Schweppe KW. Progestins and uterine leiomyoma. Gynecol Endocrinol 1999;13(Suppl 4):21-4
12. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000;65:585-92
13. Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-17
14. Palomba S, Affinito P, Tommaseli GA, et al. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998;70:111-18
15. Vu K, Greenspan DL, Wu TC, et al. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol 1998;29:359-63
16. Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844-50
17. Vollenhoven BJ, Pearce P, Herington AC, et al. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pre-treated women. Clin Endocrinol (Oxf) 1994;40: 537-44
18. Fernandez-Montoli ME, Diez-Gibert O, Samaniego JM, et al. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment. Fertil Steril 1995;63: 522-7
19. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980;16:1513-15
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54
21. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93: 5925-30
22. Viville B, Charnock-Jones DS, Sharkey AM, et al. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 1997;12:815-22
23. Jeng M-H, Shupnik MA, Bender TP, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998;139:4164-74
24. Vermeulen-Meiners C, Benedek-Jaszmann LJ, Haspels AA, et al. The endogenous concentration of estradiol and estrone in normal human post-menopausal endometrium. J Steroid Biochem 1984; 21:607-12
25. Wiegerinck MAHM, Poortman J, Donker GH, et al. In vivo uptake and subcellular distribution of tritium labelled estrogens in human endometrium, myometrium and vagina. J Clin Endocrinol Metab 1983;56:76-86